PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-929

I am certainly no better informed than any other punter. I just try to do some detective work to connect the dots.

I think it is customary in Biotech to announce when the first patient has been dosed. One of the conditions for the MND trial is that the patient mustnot have taken Riluzole for 28 days before commencement. Riluzole appears to be one of the current standards of care forMND patients. So even though recruitment has commenced there will be a lag time prior to initial dosage.

The intended number of USA dogs was 10. We can hope that recruitment is proceeding well and that meaningful data is currently being gathered. The European Covid trial as you know is not recruiting until we have safety data from MND.

I predict that the next PAA announcement will include notice that free gourmet sandwiches will be handed out at the AGM.